Vildagliptin

SKU: orb1308423

Description

Vildagliptin

Research Area

Cell Biology, Protein Biochemistry

Key Properties

• CAS Number: 274901-16-5
• MW: 303.40
• Purity: 97.81%
• Formula: C₁₇H₂₅N₃O₂
• SMILES: OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N1CCCC1C#N
• Target: Apoptosis,Proteasome,DPP-4,Ferroptosis
• Solubility: DMSO:20 mg/mL (65.92 mM);H2O:55 mg/mL (181.28 mM);Ethanol:56 mg/mL (184.57 mM)

Bioactivity

• Target IC50:
  DPP4:2.3 nM
• In Vivo:
  A the most stable DPP-4 inhibitor, Vildagliptin binds to the DPP-4 S1 and S2 catalytic sites, mimickin the transition state o the P-1 site.
• In Vitro:
  In obese Male Zucker rats, oral administration of Vildagliptin (10 μM L/kg, p.o.) during a glucose tolerance test increases GLP-1 levels, additionally stimulates Insulin secretion, and significantly reduces fluctuations in blood glucose levels. In cynomolgus monkeys treated with Vildagliptin (1 μM L/kg, p.o.), plasma DPP-IV activity is maximally inhibited (95%) approximately 2 hours post-treatment, with Inhibition >50% occurring within 30 minutes and lasting over 10 hours. In adult Male Sprague Dawley rats induced with diabetes by Streptozotocin, Vildagliptin treatment of 10 mg/kg for 32 weeks prevents nerve fiber loss. At a dosage of 60 mg/kg, Vildagliptin enhances β-cell replication and decreases apoptosis, leading to an increase in pancreatic β-cell mass, which remains elevated for 12 days post withdrawal of Vildagliptin.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DPP-4, DPP4, DPP, DPP-IV, Dipeptidyl Peptidase, dipeptidyl, cells, Apoptosis, antihyperglycemic, Caco-2, Inhibitor, inhibit, NVP-LAF 237, NVP-LAF237, NVP-LAF-237, LAF 237, LAF237, LAF-237, Ferroptosis, peptidase, Vildagliptin

Compound Identifiers

PubChem CID

5251896